secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001586
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharmaceuticals prices $2.5M registered direct offering of 2.46M shares at $1.015
--------------------------------------------------------------------------------

- Gross proceeds ~$2.5M from 2,463,058 shares at $1.015/share in registered direct offering.
- Concurrent private placement of Series E warrants to buy up to 2,463,058 shares at $0.90, exercisable for 5 years.
- Net proceeds to be used for working capital and general corporate purposes; closing expected Jan 7, 2025.
- Placement agent H.C. Wainwright receives 7% cash fee and warrants for 147,783 shares at $1.2688.
- Affiliate investors (including CEO and Executive Chairman) purchase 167,488 shares in the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925001586/0001104659-25-001586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465925001586/tm252142d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer